Business Standard

Wednesday, December 25, 2024 | 09:12 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Remdesivir reduced risk of Covid-19 deaths, but more studies needed: Gilead

The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.

Ankur Banerjee| Reuters
Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill Covid-19 patients.
The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials.
Remdesivir has been at the forefront of the battle against Covid-19 after the intravenously administered medicine helped shorten hospital recovery times in a clinical trial.
Several countries have approved the use of the treatment in severe patients but there are concerns over supply of the drug, which is also being tested as an inhaled

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in